Epratucyn (epratuzumab) / Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Epratucyn (epratuzumab) / Gilead
ACTRN12611000464965: Study of Epratuzumab versus Placebo in subjects with moderate to severe general Systemic Lupus Erythematosus (SLE)

Recruiting
3
1053
 
UCB, Inc, UCB, Inc
Systemic Lupus Erythematosus
 
 
ACTRN12612000298819: A Study to Evaluate the Safety and Tolerability of Epratuzumab in Patients With Systemic Lupus Erythematosus.

Recruiting
3
1400
 
UCB Inc, UCB Inc.
Systemic Lupus Erythematosus
 
 
IntReALL SR 2010, NCT01802814: International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010

Completed
3
700
Europe, Japan, RoW
SR-A + Epratuzumab, Epratuzumab, SR-B + Epratuzumab
Charite University, Berlin, Germany, Australian & New Zealand Children's Haematology/Oncology Group, St. Anna Kinderkrebsforschung (Co-Sponsor Austria), European Organisation for Research and Treatment of Cancer - EORTC, University Hospital Motol (Co-Sponsor Czech Republic), Copenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen), Turku University (Co-Sponsor Finland), Centre Hospitalier Universitaire de Nice, Our Lady's Chilrden's Hospital (Co-Sponsor Ireland), Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel), Ospedale Pediatrico Bambino Gesù (Co-Sponsor Italy), National Hospital Organization Nagoya Medical Center (Co-Sponsor Japan), Prinses Máxima Centrum (Co-Sponsor Netherlands), Oslo University Hospital (Co-Sponsor Oslo), Medical University of Wroclaw (Co-Sponsor Poland), Instituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa), Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain), University Children's Hospital, Zurich, Central Manchester University (Co-Sponsor United Kingdom)
Acute Lymphoblastic Leukemia (ALL)
07/23
07/23
2012-000793-30: International Study for Treatment of Standard Risk Childhood Relapsed Acute Lymphoblastic Leukemia 2010

Completed
3
1242
Europe, RoW
Epratuzumab, IMMU-103, Solution for infusion, ENDOXAN 200 mg ENDOXAN 500 mg ENDOXAN 1 g, CYTOSAR 100 mg CYTOSAR 500 mg CYTOSAR 1 g, Fortecortin, Etoposid, Zavedos, HOLOXAN, Puri-Nethol, METHOTREXAT, Mitoxantron, Oncaspar, Lanvis, Vincristine, Vindesine, Methotrexate, Methotrexat, CYTOSAR
Charité - University Hospital of Berlin, Manchester University NHS Foundation Trust, Turku University Hospital, EU Project FP7, Deutsche Kinderkrebsstiftung, Immunomedics, Deutsche kinderkrebsstiftung, Turku UNiversity Hospital
Acute lymphoblastic leukemia (ALL), Acute lymphoblastic leukemia (ALL), Diseases [C] - Cancer [C04]
 
 

Download Options